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a simple reliable method for detecting anti-HCV
antibodies in human serum that requires neither
complex reagent preparation nor expensive
instrumentation, could prove useful.
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Immunization of Peacekeeping Forces1
To the Editor: The immunization status of
military contingents arriving from different
nations for peacekeeping missions may vary
widely. This variation results from lack of
information, coordination, and financial support.
For larger missions, the United Nations (UN)
Headquarters issues recommendations about
needed vaccines; recently, operations officers
have consulted World Health Organization
experts before issuing recommendations, and
their advice, which takes into account epidemio-
logic data in the host country, has improved.
Medical officers who develop recommendations
for smaller missions must consider the
pathogenic agent; environment; host efficacy,
safety, and price of preventive measures; and
legal and ethical aspects.
Data on the incidence of vaccine-preventable
diseases within a military population that had
similar duties in the same location are rarely
available. When data from the respective region
are not available, disease incidence or preva-
lence in the host country may be substituted.
These data, however, may be misleading since
the military often does not have the same
lifestyle as the native population. Plague, for
instance, had an incidence rate of 8 per 100,000
in Namibia, but not a single case was reported in
the South African Armed Forces (unpub. SAMS
report: Disease Profile of South West Africa,
1989). If   epidemiologic documentation for a host
country is not available, data from neighboring
countries may be useful.
Travelers diarrhea is the most frequent
health problem abroad (1,2). Although the
diarrhea is self-limited and lasts an average of 1
day with appropriate treatment (4 days without),
the unproductive time may be detrimental to a
military mission. Oral vaccines against the three
most frequent causes of travelers diarrhea
(enterotoxigenic  Escherichia coli, Campylobacter
spp., and rotavirus [1,2]) are being developed;
the latter will be available soon (3). Hepatitis A,
most frequent among the vaccine-preventable
diseases (4), is 10 to 100 times more frequent
than typhoid fever (4,5). Hepatitis B occurs
mainly in expatriates, but infections have also
been observed in tourists who have had
unprotected casual sex (6). The incidence rate of
rabies is unknown, but animal bites that may
result in rabies virus transmission and thus
necessitate postexposure prophylaxis are fre-
quent (7). Only anecdotal cases of diphtheria,
tetanus, and tuberculosis have been reported (8).
Poliomyelitis, yellow fever, Japanese encephali-
tis, and plague occur only in limited parts of the
world (5). The situation may rapidly change as
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epidemics occur (e.g., diphtheria in eastern
Europe in the early and mid-1990s) (9). If
needed, the World Health Organization can
provide information on confirmed and uncon-
firmed epidemics on a weekly basis.
Travel and peacekeeping mission statistics
share similarities. In Namibia, the South African
Armed Forces had most often observed hepatitis
(unspecified), with rare cases of tuberculosis,
typhoid, and meningitis (unpub. SAMS report:
Disease Profile of South West Africa, 1989), as
did the UN mission to Namibia, where within 12
months and with 7,114 employees, seven cases of
hepatitis (mostly hepatitis A, some unspecified)
occurred (10). No other vaccine-preventable
infections were diagnosed in this UN mission.
Considering both risk (on the basis of
incidence rates) and impact of infection, the
priority for immunization (from highest to
lowest) is as follows: hepatitis A, hepatitis B,
rabies, poliomyelitis, yellow fever, typhoid fever,
influenza, diphtheria, tetanus, meningococcal
disease, Japanese encephalitis, cholera, and
measles. To administer all vaccines would be
extremely costly and may also result in an
increased rate of adverse side-effects. Immuniza-
tions against the more frequent, more severe
infections should be given priority.
If a mission is limited to one season,
environmental factors of that respective season
should be considered. This general rule is more
important for vector-borne than for vaccine-
preventable infections, except for influenza and
meningococcal disease.
Persons who are already immune (because of
previous immunization or immunity after
infection) need not be vaccinated. The latter
cause is particularly often true of hepatitis A;
troops recruited in developing countries have an
anti-hepatitis A virus seroprevalence rate close
to 100% (11). Hepatitis B immunization, except
for non- and low-responders, probably grants
lifelong protection (12); the same is likely for
measles vaccine.
Sometimes the host country may require
proof of some specific vaccination based on the
International Health Regulations (13), currently
under fundamental revision to become a more
effective tool in preventing the spread of
infections that may be a global hazard (14).
In addition to adequate epidemiologic
information and coordination between the
military, international health organizations, and
the host country, successful intervention efforts
require thorough knowledge of vaccine charac-
teristics with varying rates of efficacy and
duration of protection. Cost-benefit evaluations,
which would be very desirable, are unlikely in
areas of political instability.
Robert Steffen
Institute for Social and Preventive Medicine of the
University, Zurich, Switzerland
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Sexually Transmitted Diseases in Ukraine
To the Editor: With the political changes in
eastern Europe in the last 10 years have come
social and economic changes (1). Ukraine not